Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLAZE-4: Monoclonal Antibodies in Mild to Moderate COVID-19
NCT04634409Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of bamlanivimab, etesevimab, bebtelovimab and sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27 at Day 7. Started Oct 2020; status: completed.
02
Drugs
bamlanivimabetesevimabbebtelovimabsotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04634409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634409.